Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580172 | 0.96 | MEN1 (0.44) | LMNAMAPK10PTGS2PTGS1MEN1 | |
| SCHEMBL18137230 | 0.82 | PTGS2 (0.51) | LMNAMAPK10PTGS2PTGS1MEN1 | |
| SCHEMBL4094970 | 0.82 | PTGS2 (0.51) | LMNAMAPK10PTGS2PTGS1MEN1 | |
| SCHEMBL581560 | 0.74 | MAPK1 (0.32) | MEN1KMT2AKDM4E | |
| SCHEMBL30375516 | 0.74 | MAPK1 (0.32) | MEN1KMT2AKDM4E | |
| SCHEMBL17694188 | 0.73 | HSD17B10 (0.48) | LMNAMAPK10PTGS2PTGS1MEN1 | |
| SCHEMBL21553936 | 0.73 | PTGS2 (0.44) | LMNAMAPK10PTGS2PTGS1MEN1 | |
| SCHEMBL1830196 | 0.70 | FLT1 (0.43) | LMNAMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL9138181 | 0.70 | KDM4E (0.47) | LMNAKDM4EPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL30101051 | 0.70 | MAPK1 (0.37) | LMNAMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | LMNA 620/4885MAPK10 1365/4885PTGS2 4056/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | LMNA 637/4885MAPK10 1051/4885PTGS2 2775/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | LMNA 620/4885MAPK10 1365/4885PTGS2 4056/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | LMNA 620/4885MAPK10 1365/4885PTGS2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.